Annals of Hematology

, Volume 91, Issue 2, pp 215–221 | Cite as

Low incidence of long-term respiratory impairment in Hodgkin lymphoma survivors

  • Irit Avivi
  • Emilia Hardak
  • Beatrice Shaham
  • Mordechai Igla
  • Jacob M. Rowe
  • Eldad J Dann
Original Article
First Online:
Received:
Accepted:

Abstract

Introduction of new chemotherapy regimens over the last decade resulted in 90% survival in patients with Hodgkin lymphoma (HL), which enhances significance of abrogating chemotherapy-related long-term toxicities in young subjects. The present trial evaluated incidence of long-term respiratory complications associated with adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) or bleomycin sulfate, etoposide phosphate, doxorubicin hydrochloride (Adriamycin), cyclophosphamide, vincristine sulfate (Oncovin), procarbazine hydrochloride, and prednisone (BEACOPP). Sixty-seven HL patients, 21 treated with ABVD and 46 with BEACOPP, underwent prospective respiratory evaluation. Median follow-up from chemotherapy completion to respiratory assessment was 61 months. Abnormal lung function tests (LFT) were found in nine patients (13.6%)—three with functional dyspnea and six asymptomatic—with reduced DLCO (≤70%), VC, and TLC. Previous history of bleomycin pulmonary toxicity was found to be the only statistically significant factor for chronic respiratory impairment (75% vs. 10%, p = 0.007, relative risk (RR) = 28; 95% CI, 2.5–313). However, abnormal LFT tended to occur more frequently in patients receiving mantle field irradiation (18% vs. 9%, RR = 2.2), those who experienced respiratory infection (25% vs. 13%, RR = 2.25), and patients treated with ABVD compared to BEACOPP (19% vs. 11%, RR = 1.9). Long-term respiratory impairment in HL survivors is unusual and rarely results in functional discomfort. BEACOPP is “respiratory safe,” being associated with a nonsignificant risk for long-term respiratory dysfunction.

Keywords

Hodgkin lymphoma Respiratory toxicity Bleomycin BEACOPP 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgment

The authors are grateful to Dorit Dotan for data management, to Tania Mashiach for statistical support, and to Sonia Kamenetsky for her devoted secretarial support.

References

  1. 1.
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225–249PubMedCrossRefGoogle Scholar
  2. 2.
    Engert A, Diehl V, Franklin J, Lohri A, Dorken B, Ludwig WD, Koch P, Hanel M, Pfreundschuh M, Wilhelm M, Trumper L, Aulitzky WE, Bentz M, Rummel M, Sezer O, Muller-Hermelink HK, Hasenclever D, Loffler M (2009) Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 27:4548–4554PubMedCrossRefGoogle Scholar
  3. 3.
    Noordijk EM, Carde P, Dupouy N, Hagenbeek A, Krol AD, Kluin-Nelemans JC, Tirelli U, Monconduit M, Thomas J, Eghbali H, Aleman BM, Bosq J, Vovk M, Verschueren TA, Peny AM, Girinsky T, Raemaekers JM, Henry-Amar M (2006) Combined-modality therapy for clinical stage I or II Hodgkin’s lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 24:3128–3135PubMedCrossRefGoogle Scholar
  4. 4.
    Chow LM, Nathan PC, Hodgson DC, Jenkin D, Weitzman S, Grant RM, Manson D, Bross A, Doyle JJ, Danjoux C, Greenberg ML (2006) Survival and late effects in children with Hodgkin’s lymphoma treated with MOPP/ABV and low-dose, extended-field irradiation. J Clin Oncol 24:5735–5741PubMedCrossRefGoogle Scholar
  5. 5.
    Sleijfer S (2001) Bleomycin-induced pneumonitis. Chest 120:617–624PubMedCrossRefGoogle Scholar
  6. 6.
    Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors JM, Canellos GP, Peterson BA (2003) Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease: report of an intergroup trial. J Clin Oncol 21:607–614PubMedCrossRefGoogle Scholar
  7. 7.
    Lewis BM, Izbicki R (1980) Routine pulmonary function tests during bleomycin therapy. Tests may be ineffective and potentially misleading. JAMA 243:347–351PubMedCrossRefGoogle Scholar
  8. 8.
    Martin WG, Ristow KM, Habermann TM, Colgan JP, Witzig TE, Ansell SM (2005) Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin’s lymphoma. J Clin Oncol 23:7614–7620PubMedCrossRefGoogle Scholar
  9. 9.
    Dann EJ, Bar-Shalom R, Tamir A, Haim N, Ben-Shachar M, Avivi I, Zuckerman T, Kirschbaum M, Goor O, Libster D, Rowe JM, Epelbaum R (2007) Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood 109:905–909PubMedCrossRefGoogle Scholar
  10. 10.
    Hasenclever D, Diehl V (1998) A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med 339:1506–1514PubMedCrossRefGoogle Scholar
  11. 11.
    Borg GA (1982) Psychophysical bases of perceived exertion. Med Sci Sports Exerc 14:377–381PubMedGoogle Scholar
  12. 12.
    Fletcher CM (1952) The clinical diagnosis of pulmonary emphysema; an experimental study. Proc R Soc Med 45:577–584PubMedGoogle Scholar
  13. 13.
    Fletcher CM, Elmes PC, Fairbairn AS, Wood CH (1959) The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. Br Med J 2:257–266PubMedCrossRefGoogle Scholar
  14. 14.
    Miller MR, Crapo R, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J (2005) General considerations for lung function testing. Eur Respir J 26:153–161PubMedCrossRefGoogle Scholar
  15. 15.
    Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J (2005) Standardisation of spirometry. Eur Respir J 26:319–338PubMedCrossRefGoogle Scholar
  16. 16.
    Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, Casaburi R, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson D, Macintyre N, McKay R, Miller MR, Navajas D, Pellegrino R, Viegi G (2005) Standardisation of the measurement of lung volumes. Eur Respir J 26:511–522PubMedCrossRefGoogle Scholar
  17. 17.
    Macintyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CP, Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, Gustafsson P, Hankinson J, Jensen R, McKay R, Miller MR, Navajas D, Pedersen OF, Pellegrino R, Wanger J (2005) Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 26:720–735PubMedCrossRefGoogle Scholar
  18. 18.
    Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson DC, MacIntyre N, McKay R, Miller MR, Navajas D, Pedersen OF, Wanger J (2005) Interpretative strategies for lung function tests. Eur Respir J 26:948–968PubMedCrossRefGoogle Scholar
  19. 19.
    Kimura I, Onoshi T, Kunimasa I, Takano J (1972) Treatment of malignant lymphomas with bleomycin. Cancer 29:58–60PubMedCrossRefGoogle Scholar
  20. 20.
    Jensen JL, Goel R, Venner PM (1990) The effect of corticosteroid administration on bleomycin lung toxicity. Cancer 65:1291–1297PubMedCrossRefGoogle Scholar
  21. 21.
    Mahmood T, Mudad R (2002) Pulmonary toxicity secondary to procarbazine. Am J Clin Oncol 25:187–188PubMedCrossRefGoogle Scholar
  22. 22.
    Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ (1987) Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316:1435–1440PubMedCrossRefGoogle Scholar
  23. 23.
    Bredenfeld H, Franklin J, Nogova L, Josting A, Fries S, Mailander V, Oertel J, Diehl V, Engert A (2004) Severe pulmonary toxicity in patients with advanced-stage Hodgkin’s disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination of gemcitabine and bleomycin: a report of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 22:2424–2429PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Irit Avivi
    • 1
    • 2
  • Emilia Hardak
    • 1
  • Beatrice Shaham
    • 1
  • Mordechai Igla
    • 1
    • 2
  • Jacob M. Rowe
    • 1
    • 2
  • Eldad J Dann
    • 1
    • 2
  1. 1.Division of Pulmonary Medicine, Department of Hematology and Bone Marrow TransplantationRambam Health Care CampusHaifaIsrael
  2. 2.Bruce Rappaport Faculty of MedicineTechnion–Israel Institute of TechnologyHaifaIsrael

Personalised recommendations